## Note
nid: 1495944989407
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::!FLAG_THESE_CARDS::!DELETE, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Pembrolizumab, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions::Pembrolizumab, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::02_Rituximab,_cetuximab,_bevacizumab,_alemtuzumab,_trastuzumab::zanki_extra, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::2-RelativelyHighYield
markdown: false

### Text
<div>
  <div>
    Besides being indicated for all solid tumors bearing a PD-L1
    mutation, <b>Pembrolizumab</b> is indicated for
    {{c1::<b>refractory classical Hodgkins</b>}} <b>Lymphoma</b>
  </div>
</div>

### Extra


### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-34286723923971.jpg"><img src=
"paste-34359738368003.jpg"><img src=
"paste-34398393073667.jpg"><img src="paste-34540126994435.jpg">

### Sketchy
<img src="paste-390537081257985.jpg"><img src=
"paste-87d74ac95a67d78e1a0443bd770c17f44240fcf8.png">

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_4.png"></a>
</div>

### Additional Resources


### One by one

